KD-496

BIOLOGICAL2 trials

Sponsors

jianming xu, Peking University

Conditions

Gastric CancerPancreatic CancerSolid Tumor

Early Phase 1

NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

RecruitingNCT05583201

jianming xuGastric Cancer, Pancreatic Cancer, Solid Tumor

Start: 2022-10-13End: 2026-06-01Target: 18Updated: 2023-02-08

Phase 1

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

RecruitingNCT06134960

Peking UniversityGastric Cancer, Pancreatic Cancer, Solid Tumor

Start: 2024-11-16End: 2027-11-15Target: 12Updated: 2026-09-14

Related Papers

Phase I clinical trial evaluating dual-targeting CAR-T cells (KD-496) against CLDN18.2 and NKG2DL in advanced gastrointestinal cancers and pancreatic cancers.

Journal of Clinical Oncology2026-05-27